These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 11911842)

  • 1. A doxorubicin-CNGRC-peptide conjugate with prodrug properties.
    van Hensbergen Y; Broxterman HJ; Elderkamp YW; Lankelma J; Beers JC; Heijn M; Boven E; Hoekman K; Pinedo HM
    Biochem Pharmacol; 2002 Mar; 63(5):897-908. PubMed ID: 11911842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects.
    Garde SV; Forté AJ; Ge M; Lepekhin EA; Panchal CJ; Rabbani SA; Wu JJ
    Anticancer Drugs; 2007 Nov; 18(10):1189-200. PubMed ID: 17893520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pronounced antitumor efficacy of doxorubicin when given as the prodrug DOX-GA3 in combination with a monoclonal antibody beta-glucuronidase conjugate.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Int J Cancer; 2001 Feb; 91(4):550-4. PubMed ID: 11251980
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, in vitro stability, and antiproliferative effect of d-cysteine modified GnRH-doxorubicin conjugates.
    Li S; Zhao H; Chang X; Wang J; Zhao E; Yin Z; Mao X; Deng S; Hao T; Wang H; Yang Y
    J Pept Sci; 2019 Jan; 25(1):e3135. PubMed ID: 30467919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted antitumor prodrug therapy using CNGRC-yCD fusion protein in combination with 5-fluorocytosine.
    Li JJ; Chang SF; Liau II; Chan PC; Liu RS; Yen SH; Wang HE; Chang CA
    J Biomed Sci; 2016 Jan; 23():15. PubMed ID: 26801910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the anti-cervical cancer effect of a prodrug ：CBZ-AAN-DOX with hypoxic cell culture and tumor-bearing zebrafish models.
    Chen HC; Rui W; You SY; Liu XW; Huang J; Chen HY
    Exp Cell Res; 2020 Jun; 391(1):111980. PubMed ID: 32229193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
    Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
    Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity.
    Devy L; de Groot FM; Blacher S; Hajitou A; Beusker PH; Scheeren HW; Foidart JM; Noël A
    FASEB J; 2004 Mar; 18(3):565-7. PubMed ID: 14734647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy.
    Garsky VM; Lumma PK; Feng DM; Wai J; Ramjit HG; Sardana MK; Oliff A; Jones RE; DeFeo-Jones D; Freidinger RM
    J Med Chem; 2001 Nov; 44(24):4216-24. PubMed ID: 11708923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer.
    Houba PH; Boven E; van der Meulen-Muileman IH; Leenders RG; Scheeren JW; Pinedo HM; Haisma HJ
    Br J Cancer; 2001 Feb; 84(4):550-7. PubMed ID: 11207053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts.
    Khan SR; Denmeade SR
    Prostate; 2000 Sep; 45(1):80-3. PubMed ID: 10960846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of Long-Acting CNGRC-CPG2 Fusion Proteins: New Derivatives to Overcome Drug Immunogenicity of Ligand-Directed Enzyme Prodrug Therapy for Targeted Cancer Treatment.
    Al-Mansoori L; Al Qahtani AD; Elsinga P; Goda SK
    Technol Cancer Res Treat; 2021; 20():15330338211057371. PubMed ID: 34802309
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor-specific gene delivery mediated by a novel peptide-polyethylenimine-DNA polyplex targeting aminopeptidase N/CD13.
    Moffatt S; Wiehle S; Cristiano RJ
    Hum Gene Ther; 2005 Jan; 16(1):57-67. PubMed ID: 15703489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13).
    Cui SX; Zhang HL; Xu WF; Qu XJ
    Eur J Pharmacol; 2014 Jul; 734():50-9. PubMed ID: 24726845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Water-soluble polymers for targeted drug delivery to human squamous carcinoma of head and neck.
    Nan A; Ghandehari H; Hebert C; Siavash H; Nikitakis N; Reynolds M; Sauk JJ
    J Drug Target; 2005 Apr; 13(3):189-97. PubMed ID: 16036307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liposome-mediated targeting of enzymes to cancer cells for site-specific activation of prodrugs: comparison with the corresponding antibody-enzyme conjugate.
    Fonseca MJ; Jagtenberg JC; Haisma HJ; Storm G
    Pharm Res; 2003 Mar; 20(3):423-8. PubMed ID: 12669963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting by doxorubicin-RGD-4C peptide conjugate in an orthotopic mouse hepatoma model.
    Kim JW; Lee HS
    Int J Mol Med; 2004 Oct; 14(4):529-35. PubMed ID: 15375578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.